Reimbursement Support
CareZ can help facilitate reimbursement
Through CareZ, you will have access to skilled representatives who are highly experienced
in dealing with insurance-related questions and finding support for qualified patients
who are uninsured or underinsured, or who cannot afford their therapy. These experts
can assist you with reimbursement and other related issues, including:
- Providing guidance when your insurance company has denied coverage
- Supplying therapy codes for insurance and medical forms
- Reporting trends in coverage and reimbursement
- Explaining new federal and state policies and how they might impact you
- Providing literature searches (medical and clinical) to support a particular choice
of therapy
To speak with a CareZ Case Manager about a specific reimbursement issue, call 1-800-415-2167.
Online information available at CSLBehring.com
Our online Reimbursement Resource Center is designed to provide helpful insights
for understanding medical service costs and related insurance matters, including
health insurance reimbursement for Zemaira. Through the Reimbursement Resource Center,
you can obtain information about:
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.